[Antiphospholipid syndrome].
Atsumi
Tatsuya
T
Department of Medicine II, Hokkaido University Graduate School of Medicine.
Koike
Takao
T
D017153:Antibodies, Anticardiolipin; D017152:Antibodies, Antiphospholipid; D000925:Anticoagulants / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D006023:Glycoproteins / Q000276:immunology; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D016682:Lupus Coagulation Inhibitor; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011516:Prothrombin / Q000276:immunology; D012015:Reference Standards; D015912:Thrombolytic Therapy; D014859:Warfarin / Q000627:therapeutic use; D053482:beta 2-Glycoprotein I
D017153:Antibodies, Anticardiolipin; D017152:Antibodies, Antiphospholipid; D000925:Anticoagulants; D006023:Glycoproteins; D016682:Lupus Coagulation Inhibitor; D010975:Platelet Aggregation Inhibitors; D053482:beta 2-Glycoprotein I; D014859:Warfarin; D011516:Prothrombin; D006493:Heparin